TY - JOUR
T1 - Anticipating potential linezolid-SSRI interactions in the general hospital setting
T2 - An MAOI in disguise
AU - Sola, Christopher L.
AU - Bostwick, J. Michael
AU - Hart, Dionne A.
AU - Lineberry, Timothy W.
PY - 2006/3
Y1 - 2006/3
N2 - Linezolid, a novel antimicrobial with activity against gram-positive bacteria including pathogens resistant to traditional antimicrobials, also inhibits monoamine oxidase. This latter property can cause potentially lethal adverse interactions with antidepressant medications. Long known to psychiatrists, monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome. We review the pharmacology of MAOIs and describe 3 clinical situations in which linezolid-selective serotonin inhibitor (SSRI) interactions, actual or potential, figured prominently.
AB - Linezolid, a novel antimicrobial with activity against gram-positive bacteria including pathogens resistant to traditional antimicrobials, also inhibits monoamine oxidase. This latter property can cause potentially lethal adverse interactions with antidepressant medications. Long known to psychiatrists, monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome. We review the pharmacology of MAOIs and describe 3 clinical situations in which linezolid-selective serotonin inhibitor (SSRI) interactions, actual or potential, figured prominently.
UR - http://www.scopus.com/inward/record.url?scp=33644666120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644666120&partnerID=8YFLogxK
U2 - 10.4065/81.3.330
DO - 10.4065/81.3.330
M3 - Article
C2 - 16529136
AN - SCOPUS:33644666120
SN - 0025-6196
VL - 81
SP - 330
EP - 334
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 3
ER -